Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hiroaki Kume (Osakasayama, Japan), Hiroaki Kume, Osamu Nishiyama, Yuji Higashimoto, Yuji Tohda. Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases. Eur Respir J 2016; 48: Suppl. 60, 4050

Member's Comments

No comment yet.

Related content which might interest you: COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Severity of airflow obstruction and multicomponent disease staging of COPD in the real-world primary care in Greece: The AEOLUS study Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities Year: 2014 LATE-BREAKING ABSTRACT: Eosinophilic inflammation in COPD: During clinical stability and exacerbations. The AERIS study Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Clinical and inflammatory characteristics of 'unreported' COPD exacerbations Source: Annual Congress 2013 –COPD mechanisms Year: 2013 The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Compare clinical effectiveness of various types of bronchodilators in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Eosinophilia as marker of outcome in hospitalised patients with AECOPD Source: Annual Congress 2013 –COPD and infections Year: 2013 RT protocol reduces AECOPD readmissions Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Pulmonary diffusing capacity and the risk of fractures in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – COPD markers Year: 2014 Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 COPD: GOLD 2011 and implications for clinical practice Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Are there any differences between Tunisian and European COPD phenotypes? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Frequency of osteoporosis and pulmonary diffusing capacity in patients with chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – COPD: points to ponder Year: 2014 Variability in clinical practice for chronic obstructive pulmonary disease in outpatient clinics Source: International Congress 2015 – Different data in COPD Year: 2015 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD mechanisms Year: 2013